Short answer
PRECIGEN, INC. (PGEN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $74M with net income of $36M.
Q3 2026 key financials · XBRL
- Revenue
- $74M
- +34.9% QoQ
- Net income
- $36M
- +124.4% YoY · +78.2% QoQ
- Operating margin
- 52.1%
- EPS (diluted)
- $0.09
- +108.3% YoY · +80.0% QoQ
Source: XBRL data from the PRECIGEN, INC. (PGEN) Q3 2026 10-Q on SEC EDGAR. USD.
PRECIGEN, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $74.1M, up >200% YoY from $2.9M, driven by Papzimeos product revenue of $72.9M
- Operating margin 52.1% vs (1,180.4)% YoY, with operating income $38.7M vs loss of $34.5M
- Papzimeos strongest product line, $72.9M revenue; collaboration and licensing revenue weakest, $0 vs $1.8M YoY
- Q3 operating cash flow $11.9M positive; September 30 cash $15.0M plus investments of $36.0M
- Outlook: continued Papzimeos commercialization, with headwinds from 127-day customer payment terms and potential additional capital needs
Risk Factors
- No additional material risk-factor changes since the Annual Report
- Carried-forward risks may materially affect operating results
- Carried-forward risks may materially affect financial condition
- SEC filings contain additional relevant risk disclosures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PRECIGEN, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.